Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
December 2023 CLL Bloodline – Over the course of a year of monthly meetings, The CLL Society Bloodline will teach the BASICS needed to understand CLL.
National Family Caregivers Month Quotes on Being a Care Partner to a Loved One With Chronic Lymphocytic Leukemia November is National Family Caregivers Month, and we are honoring all the vital
Epcoritamab, a novel subcutaneous (an under-the-skin injection) CD3xCD20 bispecific antibody, resulted in a 62% response rate in high-risk, difficult-to-treat relapsed or refractory (R/R) CLL patients that so far appears to be durable.
Five years after completing venetoclax – obinutuzumab to treat chronic lymphocytic leukemia (CLL), over half of the treatment-naive patients remained in remission, and over 60% did not require second-line treatment, including many high-risk patients.
Following discontinuation of a non-covalent Bruton tyrosine kinase inhibitor (BTKi), venetoclax is clinically active in patients with CLL or Richter transformation who have not received it in the past. CAR-T therapy may also be an option, but this requires further study.
With the introduction of acalabrutinib and zanubrutinib, which have fewer side effects, the hope is that fewer patients will need to stop treatment due to adverse events and that they will be able to stay on BTKi therapy for longer.
Over the course of a year of monthly meetings, The CLL Society Bloodline will teach the BASICS needed to understand CLL. It will also provide news, help with the acronyms and new vocabulary words, and offer simple fun quizzes. The cycle restarts and it is updated annually.
We discuss enitociclib, an experimental CDK9 inhibitor in development for treating NHL and CLL.
Adding venetoclax to ibrutinib in high-risk patients with chronic lymphocytic leukemia (CLL) who have been on ibrutinib for more than one year was very effective in helping patients reach undetectable measurable residual disease (uMRD).
One click to our most popular content.
